Beyond the breakthrough for RAS-driven cancers
Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04610-4 Two early clinical studies of selective KRASG12D inhibitors show encouraging activity in advanced cancers with G12D mutations, signaling a transformative change in…
Read the full story at Nature Medicine ↗
ImpactNotable 44/100
Why it mattersRule-based estimate: event keywords (+8); trust 10/10.
RegionsGlobal
Published4 d ago (Tue, 15 Sep 2026 00:00:00 GMT)
RetrievedWed, 16 Sep 2026 00:01:10 GMT via rdf
ClassifiedWed, 16 Sep 2026 03:31:10 GMT by heuristic
AuthorRich C. King